Reply to “Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence”
Open Access
- 7 April 2026
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 99 (6) , 1614-1615
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and FunctionCNS Drugs, 2025
- Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitroInternational Immunopharmacology, 2023
- Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional propertiesmAbs, 2013